The Combination of Goodpasture syndrome and granulomatosis with polyangiitis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Goodpasture syndrome (SG) is a rare autoimmune organ-specific disease characterized by clinical manifestations in the form of a combination of rapidly progressive glomerulonephritis with pulmonary hemorrhage and the presence of glomerular basement membrane antibodies. description of the clinical case. a clinical case of a patient with anca-sv and gs is presented. the untimely seeking medical advice, late diagnosis of gs and anca-sv, which presents certain difficulties for doctors of various specialties due to the rarity of these diseases, little known to a wide range of medical practitioners, multi-organ manifestations and a variety of clinical options for the course of the disease do not always allow to suspect their presence at the early stages.

Full Text

Restricted Access

About the authors

M. S Vetsheva

Sechenov First Moscow State Medical University

Doctor of Medical Sciences, Professor at the Department of Anesthesiology and Emergency Medicine Moscow, Russia

O. L Podkorytova

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: o-podkorytova@yandex.ru
PhD in Medical Sciences, Head of the Resuscitation and Intensive Care Unit №2 (for nephrological patients) Moscow, Russia

L. Yu Artyukhina

City Clinical Hospital № 52 of the Moscow Healthcare Department

PhD in Medical Sciences, Head ofthe Nephrology Department № 1 Moscow, Russia

K. E Loss

City Clinical Hospital № 52 of the Moscow Healthcare Department

Anesthesiologist-Intensivist, Resuscitation and Intensive Care Unit № 2 (for nephrological patients) Moscow, Russia

M. A Lysenko

City Clinical Hospital № 52 of the Moscow Healthcare Department

Doctor of Medical Sciences, Professor, Chief Physician Moscow, Russia

References

  1. Мухин Н.А. Синдром Гудпасчера: патогенез, диагностика, лечение. Фарматека. 2011;18:8-14
  2. Naidoo S, Waller S. Anti-GBM antibodies co-exist with MPO-ANCA in a 4-year-old girl with acute renal failure. Pediatr. Nephrol. 2009;24(1):215-216.
  3. Лечение гломерулонефрита, обусловленного антителами к гломерулярной базальной мембране. Клинические практические рекомендации KDIGO по лечению гломерулонефритов. Нефрология и диализ. 2014;136-140.
  4. Hellmark T., Segelmark M. Diagnosis and classification of Goodpasture’s disease (anti-GBM). J. Autoimmun. 2014;48-9:108-112
  5. Yang R., Cui Z., Zhao J., Zhao M.H. The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease. Clin. Immunol. 2009;133(2):245-250.
  6. Bayat A., Kamperis K, Herlin T. Characteristics and outcome of Goodpasture’s disease in children. Clin. Rheumatol. 2012;31(12): 1745-1751.
  7. Greco A., et al. Goodpasture’s syndrome: A clinical update. Autoimmun. Rev. 2014;14(3):246-253.
  8. Persson U, Hertz J.M., Carlsson M., et al. Patients with Goodpasture’s disease have two normal COL4A3 alleles encoding the NC1 domain of the type IV collagen alpha 3 chain. Nephrol. Dial. Transplant. 2004;19:2030-2035.
  9. Hudson B.G., Tryggvason K., Sundaramoorthy M., Neil son E.G. Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. N. Engl. J. Med. 2003;348:2543-2556.
  10. Zou J., Henderson L., Thomas V., et al. Presentation of the Goodpasture autoantigen requires proteolytic unlocking steps that destroy prominent T cell epitopes. J. Am. Soc. Nephrol. 2007;18(3):771-779.
  11. Cui Z., Zhao M.-H. Advances in human antiglomerular membrane disease. Nat. Rev. Nephr. 2011;7:(12):697- 705.
  12. Rutgers A., Meyers K.E., Canziani G., et al. High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients.to alpha 3 (IV) NC1 collagen. Kidney Int. 2000;58:115-122.
  13. Ohlsson S., Herlitz H., Selga D., et al. Circulating Anti-Glomerular Basement Membrane Antibodies with Predominance of Subclass IgG4 and False-Negative Immunoassay Test Results in Anti-Glomerular Basement Membrane Disease. Am. J. Kidney Dis. 2014;63(2):289-293.
  14. Salama A.D., Chaudhry A.N., Ryan J.J., et al. In Goodpasture’s disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3 (IV) NC1. J. Am. Soc. Nephrol 2001;12:1908-1915.
  15. Silvarino R., Noboa O., Cervera R. Anti-glomerular basement membrane antibodies. Israel Med. Associat. J. 2014;16(11):727-732.
  16. Meyera D., Colesb A., Oyuelac P., et al. Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. Mult. Scleros. Relat. Disord. 2013;2(1):60-63.
  17. Dean E.G., Wilson G.R., Li M., et al. Experimental autoimmune Goodpasture’s disease: a pathogenetic role for both effector cells and antibody in injury. Kidney Int. 2005;67:566-575.
  18. Okada H., Moriwaki K., Kalluri R., et al. Inhibition of monocyte hemoattractant protein-1 expression in tubular epithelium attenuates tubulointerstitial alteration in rat Goodpasture syndrome. Kidney Int. 2000;57:927-936.
  19. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int. 2012;Suppl.(2):139-274.
  20. Kuroda T., Yoshida Y, Kamiie J, et al. Expression of MMP-9 in mesangial cells and its changes in anti-GBM glomerulonephritis in WKY rats. Clin Exp Nephrol 2004;8(3):206-215.
  21. Мухин Н.А. Синдром Гудпасчера. В кн. Нефрология (рук-во для врачей). М., 2000. [Mukhin N.A. Goodpasture Syndrome. V kn. Nefrologiya (ruk-vo dlya vrachey). M., 2000. (In Russ.)].
  22. Salama A.D., Levy J.B., Lightstone L., Pusey C.D. Goodpasture’s disease. Lancet. 2001;358:917-920.
  23. Touzot M., Poisson J., Faguer S., et al. Rituximab in anti-GBM disease: A retrospective study of 8patients. J. Autoimmun. 2015;60:74-79.
  24. Laczika K., Knapp S., Derfler K., et al. Immunoadsorption in Goodpasture’s syndrome. Am. J. Kidney Dis. 2000;36:392-25.
  25. Baumgartner I., Gmur J., Fontana A., et al. Recovery from life threatening pulmonary hemorrhage in Goodpasture’s syndrome after plasmapheresis and subsequent pulse dose cyclosphosphamide. Clin. Nephrol. 1995;43:68-70.
  26. Garcia-Canton C., Toledo A., Palomar R., et al. Goodpasture’s syndrome treated with mycofenolat mofetil. Nephrol. Dial. Transplant. 2000;15:920-922.
  27. Takeda S., Takahashi M., Sado Y., et al. Prevention of glomerular crescent formation in glomerulonephritis by mycophenolate mofetil in rats. Nephrol. Dial. Transplant. 2004;19(9):2228-2236.
  28. Huang L., Garcia G., Lou Y., et al. Antiinflammatory and renal protective actions of stanniocalcin-1 in a model of anti-glomerular basement membrane glomerulonephritis. Am. J. Pathol. 2009;174(4):1368-1378.
  29. Asgeirsdottir S.A., Zwiers P.J., Morselt H.W., et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasoneloaded AbEsel liposomes. Am. J. Physiol. Renal. Physiol. 2008;294(3):554-561.
  30. Garcia G.E., Truong L.D., Li P., et al. Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis. Am. J. Pathol. 2007;170(5):1485-1496.
  31. Leh S., Vaagnes O., Margolin S.B., et al. Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. Nephrol. Dial. Transplant. 2005;20(1):71-82.
  32. Bayat A., Kamperis K., Herlin T. Characteristics and outcome of Goodpasture’s disease in children. Clin. Rheumatol. 2012;31:12:1745-1751.
  33. West S.C., Arulkumaran N., Ind P.W., et al. Pulmonary-renal syndrome: a life threatening but treatable condition. Postgrad. Med. J. 2013;89:1051: 274-283.
  34. Watts R.A. Epidemiology of vasculitis. R.A. Watts, D.G.I. Scott. Vasculitis. 2nd ed. Oxford: Oxford University Press. 2008. С. 7-22.
  35. Ntatsaki E. Epidemiology of ANCA-associated vasculitis. E. Ntatsaki, R.A. Watts, D.G. Scott. Rheum. Dis. Clin. North Am. 2010;565:447-461.
  36. Savage C.O. Pathogenesis of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis/C.O. Savage. Clin. Exp. Immunol. 2011;164:23-26.
  37. Stegeman C.A., Cohen Tervaert J.W., Sluiter W.J. et al. Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener’s granulomatosis. Ann. Intern. Med. 1994;120:12-17.
  38. Popa E.R., Stegeman C.A., Abdulahad W.H., van der Meer B., Arends J., Manson W.M., Bos N.A., Kallenberg C.G., Tervaert J.W. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener’s granulomatosis. Rheumatol. (Oxford) 2007;46(6):1029-1033.
  39. Van der Woude F., Rasmussen N., Lobatto S., et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet. 1985;1:425-429.
  40. Kain R., et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat. Med. 2008;14:1088-1096.
  41. Roth A.J., et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J. Am. Soc. Nephrol. 2012;23:545-555.
  42. Yates M., Watts R.A., Bajema I.M., et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 2016 Jun 23. pii: annrheumdis-2016-209133. Doi: 10.1136/ annrheumdis-2016-209133.
  43. Бекетова Т.В. АНЦА-ассоциированный системный васкулит. Нефрология. Национальное руководство. М., 2014. [Beketova T.V. ANTSA-assotsiirovannyy sistemnyy vaskulit. Nefrologiya. Natsional’noye rukovodstvo. M., 2014. (In Russ.)].
  44. Kallenberg C.G. Pathogenesis of ANCA-associated vasculitis, an update. Clin. Rev. Allergy Immunol. 2011;41(2):224-231.
  45. Gomez-Puerta J.A., Bosch X. Anti-neutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update. Am. J. Pathol. 2009;175:1790-1798.
  46. Falk R.J., Terrell R.S., Charles L.A., Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl. Acad. Sci. 1990;87:4115-4119.
  47. Booth A., Harper L., Hammad T., Bacon P., Griffith M., Levyet J., et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 2004;820:717-721.
  48. Shlomchik M.J., Craft J.E., Mamula M.J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 2001;200:147-153.
  49. Voswinkel J, Mueller A., Kraemer J.A., Lamprecht P., Herlyn K., Holl-Ulrich K., Feller A.C., Pitann S., Gause A., Gross W.L. B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VHgenes from endonasal lesions. Ann. Rheum. Dis. 2006;1200:859-64.
  50. Gross W.L. Immunopathology and newtherapeutic considerations in ANCA-associated vasculitides. Autoimmun. Rev. 2004;120:47-48.
  51. Harper L, Savage С. Pathogenesis of ANCA-associated systemic vasculitis. J. Pathol. 2000;190:149-159.
  52. Vital A., Vital C, Viallard J.F., Ragnaud J.M., Canron M.H., Lagueny A. Neuro-muscular biopsy in Churg-Strauss syndrome: 24 cases. J. Neuropathol. Exp. Neurol. 2006;65(2):187-92.
  53. Berden A.E., Ferrario F, Hagen E.C., Jayne D.R., Jennette J.C., Joh K., Neumann I., Noel L.H., Pusey C.D., Waldherr R., Bruijn J.A., Bajema I.M. Histopathologic lassification of ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. 2010;21(10):1628-1636.
  54. KDIGO Clinical Practice Guideline for glomerulonephritis. Kidney Int Suppl 2012; 2:139-274.
  55. Бекетова Т.В. Перспективы применения ритуксимаба при васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами. Научно-практическая ревматология, 2010;4(1):80-90.
  56. Specks U., Merkel P.A., et al, for the RAVE-ITN Research Grou. Efficacy of Remission-Induction Regimens for ANCA - Associated Vasculitis. N. Engl. J. Med. 2013;369:417-427.
  57. Бекетова Т.В., Александрова Е.Н., Новоселова Т.М. и др. Российский опыт применения моноклональных антител к В-лимфоцитам (ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научно-практическая ревматология. 2014;52(2):147-158.
  58. Hebert L.A., Alvarado A., Rovin B. Rituximab or Azathioprine Maintenance in ANCA-Associated Vasculitis. N. Engl. J. Med. 2015;372:385-387.
  59. Бекетова Т.В. Европейские (EULAR/ERA-EDTA) рекомендации по диагностике и лечению АНЦА-ассоциированных системных васкулитов. 2016. Научно-практическая ревматология. 2017;55(1):12-16.
  60. Jayne D.R.W., Gaskin G., Rasmussen N., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 2007;18:2180-2188.
  61. Ward D.M. Conventional apheresis therapies: a review. J. Clin. Apher. 2011;26 (5):230-238.
  62. Gregersen J.W., Kristensen T., Krag S.R., Birn H., Ivarsen P. Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis. Clin. Exp. Rheumatol. 2012;30(1 Suppl. 70):39-47.
  63. Chen Y., Yang L., Li K., et al. Double Filtration Plasmapheresis in the Treatment of Antineutrophil Cytoplasmic Autoantibody Associated Vasculitis with Severe Renal Failure: A Preliminary Study of 15 Patients. Ther. Apher. Dial. 2016; 20(2):183-188.
  64. Klemmer P.J., Chalermskulrat W., Reif M.S., et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with Small-Vessel vasculitis. Am. J. Kidney Dis. 2003;42:1149-1153.
  65. Levy J.B., Hammad T., Coulthart A., et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66:1535-1541.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies